Lilly Xigris Efficacy Driven By Chronically Ill Patients, FDA Analyses Show
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Xigris’ greater efficacy in patients with chronic health problems may account for the minimal effect on hospital discharge seen in the pivotal trial of the sepsis agent, FDA review documents maintain.
You may also be interested in...
Lilly’s Search For Sepsis Biomarkers Could Provide Early Signal For Xigris Use
Lilly is looking for sepsis biomarkers that could aid Xigris administration, exec tells FDA seminar. Data suggests Xigris, a form of activated protein C, has higher survival rates when administered early; biomarkers could be signal for use. Studies of diagnostic/prognostic role of protein C are underway
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product